Suppr超能文献

一名患有VEXAS综合征的患者对COVID-19 mRNA疫苗的不良反应

Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome.

作者信息

Ciprian Giulio

机构信息

Internal Medicine, Roger Williams Medical Center, Providence, USA.

出版信息

Cureus. 2022 Mar 24;14(3):e23456. doi: 10.7759/cureus.23456. eCollection 2022 Mar.

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a rare genetic disorder originating from a somatic mutation in the hematopoietic stem cells. This syndrome was first described in 2020 and carries many clinical features that other conditions cannot explain. Widespread autoinflammation is the primary process the disease presents, with high morbidity and mortality in those who show signs of bone marrow failure. Treatment is complex, and response to current therapies is poor. Long-term prognosis carries a mortality of 50%. In addition, the advancement of new-generation messenger ribonucleic acid (mRNA) vaccines raises concerns about their safety in this population since it could trigger a vaccine-related autoimmune response. This case describes the hospital course of a male in his 50s exhibiting an unexplained cutaneous reaction to an mRNA COVID-19 vaccine. He was later diagnosed with VEXAS syndrome based on symptoms presentation and diagnostic workup.

摘要

VEXAS(空泡、E1酶、X连锁、自身炎症性、体细胞)综合征是一种罕见的遗传性疾病,起源于造血干细胞中的体细胞突变。该综合征于2020年首次被描述,具有许多其他病症无法解释的临床特征。广泛的自身炎症是该疾病呈现的主要过程,在出现骨髓衰竭迹象的患者中发病率和死亡率都很高。治疗复杂,对当前疗法的反应不佳。长期预后的死亡率为50%。此外,新一代信使核糖核酸(mRNA)疫苗的推广引发了对其在该人群中安全性的担忧,因为它可能引发与疫苗相关的自身免疫反应。本病例描述了一名50多岁男性因对mRNA新冠疫苗出现不明原因的皮肤反应而住院的过程。他后来根据症状表现和诊断检查被诊断为VEXAS综合征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0230/9034849/d3d7540e6727/cureus-0014-00000023456-i01.jpg

相似文献

1
Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome.
Cureus. 2022 Mar 24;14(3):e23456. doi: 10.7759/cureus.23456. eCollection 2022 Mar.
3
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
J Clin Med. 2024 Feb 12;13(4):1049. doi: 10.3390/jcm13041049.
4
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
J Allergy Clin Immunol. 2022 Jan;149(1):432-439.e4. doi: 10.1016/j.jaci.2021.05.014. Epub 2021 May 25.
7
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Exp Hematol Oncol. 2021 Mar 19;10(1):23. doi: 10.1186/s40164-021-00217-2.
8
VEXAS syndrome with cutaneous nodules.
Dermatol Reports. 2021 Dec 28;14(2):9414. doi: 10.4081/dr.2022.9414. eCollection 2022 Jun 16.
9
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Semin Hematol. 2021 Oct;58(4):204-211. doi: 10.1053/j.seminhematol.2021.10.007. Epub 2021 Oct 22.
10
Clinical Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome: A Narrative Review.
Cureus. 2024 Jan 27;16(1):e53041. doi: 10.7759/cureus.53041. eCollection 2024 Jan.

引用本文的文献

1
Clinical features and treatments of VEXAS syndrome in critical care: a scoping review.
Crit Care. 2025 Apr 17;29(1):154. doi: 10.1186/s13054-025-05390-y.
2
Neurological manifestations in patients with VEXAS syndrome.
J Neurol. 2025 Feb 1;272(2):181. doi: 10.1007/s00415-025-12902-x.
3
Ocular and orbital manifestations in VEXAS syndrome.
Eye (Lond). 2024 Jun;38(9):1748-1754. doi: 10.1038/s41433-024-03014-3. Epub 2024 Mar 28.
4
VEXAS Syndrome-Diagnostic Clues for the Dermatologist and Gaps in Our Current Understanding: A Narrative Review.
JID Innov. 2023 Oct 29;4(1):100242. doi: 10.1016/j.xjidi.2023.100242. eCollection 2024 Jan.
5
Recurrent superior orbital fissure syndrome associated with VEXAS syndrome.
J Ophthalmic Inflamm Infect. 2023 Sep 7;13(1):39. doi: 10.1186/s12348-023-00362-1.
6
VEXAS Syndrome-Review.
Glob Med Genet. 2023 Jul 10;10(3):133-143. doi: 10.1055/s-0043-1770958. eCollection 2023 Sep.

本文引用的文献

2
Azacytidine Treatment for VEXAS Syndrome.
Hemasphere. 2021 Nov 17;5(12):e661. doi: 10.1097/HS9.0000000000000661. eCollection 2021 Dec.
3
Toward a pathophysiology inspired treatment of VEXAS syndrome.
Semin Hematol. 2021 Oct;58(4):239-246. doi: 10.1053/j.seminhematol.2021.09.001. Epub 2021 Oct 5.
5
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome.
JAMA Dermatol. 2021 Nov 1;157(11):1349-1354. doi: 10.1001/jamadermatol.2021.3344.
7
Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan.
Ann Rheum Dis. 2021 Nov;80(11):1501-1502. doi: 10.1136/annrheumdis-2021-220876. Epub 2021 Jun 21.
8
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
J Allergy Clin Immunol. 2022 Jan;149(1):432-439.e4. doi: 10.1016/j.jaci.2021.05.014. Epub 2021 May 25.
9
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome.
Blood. 2021 Jul 1;137(26):3676-3681. doi: 10.1182/blood.2020010286.
10
Therapeutic options in VEXAS syndrome: insights from a retrospective series.
Blood. 2021 Jul 1;137(26):3682-3684. doi: 10.1182/blood.2020010177.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验